Prevalence of Polyendocrine Metabolic Ovarian Syndrome in Patients Diagnosed With Acne Vulgaris in Sohag University Hospital

September 10, 2026 updated by: Omar Shazly Saleh, Sohag University
The aim of this study is to determine the prevalence of polyendocrine metabolic ovarian syndrome (PMOS) among female patients diagnosed with acne vulgaris in Sohag university hospital

Study Overview

Status

Recruiting

Conditions

Detailed Description

A cross-sectional observational study designed to determine the prevalence of polycystic ovary syndrome (PCOS) among patients diagnosed with acne vulgaris attending Sohag University Hospital.

Study Type

Observational

Enrollment (Estimated)

90

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Egypt
      • Sohag, Egypt, 82511
        • Recruiting
        • Sohag University Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Female patients diagnosed with acne vulgaris

Description

Inclusion Criteria:

  • Female patients at childbearing age ( 15 - 49 years) (World Health, 2024).

  • Patients clinically diagnosed with acne vulgaris.

    • Clinical diagnosis of Acne vulgaris:

    o Presence of comedones (open/black and closed/white), inflammatory lesions (papules, pustules, or nodules), with or without post-acne changes such as hyperpigmentation or scarring (Oge et al., 2019).

  • Patients diagnosed with polyendocrine metabolic ovarian syndrome (PMOS) according to the 2023 International Evidence-based Guideline for PCOS diagnosis.

  • Diagnostic criteria for PMOS diagnosis in adults : (Forslund et al., 2024).

    • Diagnosis of PMOS will be based on the presence of at least two of the following three criteria after exclusion of other etiologies:

      1. Ovulatory dysfunction:

      • Irregular menstrual cycles or oligo/anovulation. 2. Clinical and/or biochemical hyperandrogenism:

      • Clinical signs such as hirsutism and/or acne, or biochemical evidence of elevated androgen levels.

        3. Polycystic ovarian morphology (PCOM):

      • Polycystic ovaries detected by pelvic ultrasound, or elevated anti-Müllerian hormone (AMH) level in adults as an alternative to ultrasound.
    • Most women with PMOS have a combination of hyperandrogenism and irregular cycles, and in these cases there is no need to assess PCOM. In adolescents, both ovulatory dysfunction and hyperandrogenism are mandatory (Forslund et al., 2024).
  • Patients willing to participate and provide informed consent.

Exclusion Criteria:

  • Pregnant women.
  • Lactating mothers
  • Women diagnosed with other acneiform lesions
  • Women on certain drug treatments like oral contraceptive pills, ovarian stimulating drugs and oral hypoglycemic agents like metformin.
  • Patients with incomplete clinical data or who refuse to participate in the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Patients diagnosed with acne vulgaris

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Prevalence of polyendocrine metabolic ovarian syndrome (PMOS) among patients diagnosed with acne vulgaris in Sohag university hospital
Time Frame: Over 1 year
Over 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sohag University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 9, 2026

Primary Completion (Estimated)

February 8, 2027

Study Completion (Estimated)

May 1, 2027

Study Registration Dates

First Submitted

September 10, 2026

First Submitted That Met QC Criteria

September 10, 2026

First Posted (Actual)

September 16, 2026

Study Record Updates

Last Update Posted (Actual)

September 16, 2026

Last Update Submitted That Met QC Criteria

September 10, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Soh-Med-26-8-8MS

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe